RayKnowChina Research Map
Shortlist0

RecruitingNeuroblastomaPhase 1

Registered title, quoted from ClinicalTrials.gov

Phase I Study of Umbilical Cord Blood Natural Killer (NK) Cell Therapy for Children With High-risk, R/R Neuroblastoma.

An open trial on neuroblastoma, registered on ClinicalTrials.gov. Led by Sun Yat-sen University Cancer Center; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 13 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)Sun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06631391, read on 13 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 1 day to 18 years; sex: all

    Registered eligibility fields

  2. Suffering from the following cardiovascular diseases: grade II or higher myocardial ischemia or myocardial infarction, poorly controlled arrhythmias (including QTc interval ≥450 ms for males and ≥470 ms for females); according to the NYHA standard (Appendix Three), class III-IV heart failure, or echocardiography indicating left ventricular ejection fraction (LVEF) <50%;

    Exclusion criterion 2

  3. Bone marrow suppressive chemotherapy: At least 21 days after the last bone marrow suppressive chemotherapy (if nitrosoureas were used previously, then 42 days);

    Inclusion criterion 7

    X-ray therapy (XRT): At least 14 days after local palliative XRT (small field port); if other substantial bone marrow (BM) irradiation is involved, including prior radioactive iodine metaiodobenzylguanidine (131I-MIBG) treatment, it must end at least 42 days ago;

    Inclusion criterion 10

    Stem cell infusion without total body irradiation (TBI): No active graft-versus-host disease, must have ended at least 56 days after transplantation or stem cell infusion;

    Inclusion criterion 11

  4. Karnofsky (≥16 years old) or Lansky (<16 years old) physical status score (Appendix II) of at least 50;

    Inclusion criterion 3

  5. Absolute neutrophil count (ANC) ≥1.0×10\^9/L (if bone marrow involvement, then ANC ≥0.5×10\^9/L)

    Inclusion criterion 13

    Platelet count (PLT) ≥75×10\^9/L (if bone marrow involvement, then PLT ≥20×10\^9/L)

    Inclusion criterion 14

    Bilirubin ≤1.5 times the upper limit of normal (ULN)

    Inclusion criterion 15

    Creatinine ≤1.5 times ULN (calculated using the standard Cockcroft-Gault formula)

    Inclusion criterion 16

    ALT/AST ≤3 times ULN (if there is liver metastasis, this can be relaxed to 5 times ULN)

    Inclusion criterion 17

    Coagulation disorders (INR >1.5 or prothrombin time (PT) >ULN +4 seconds or APTT >1.5 ULN), with a tendency to bleed or currently receiving thrombolytic or anticoagulant therapy;

    Exclusion criterion 4

  6. HBsAg positive and HBV DNA exceeds the upper limit of normal

    Exclusion criterion 24

    Anti-HCV positive and HCV RNA positive

    Exclusion criterion 25

    HIV positive

    Exclusion criterion 26

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; scans and measurable lesions; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06631391, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

All of the following criteria must be met in order to be eligible for this trial:

  • Agree to participate in the trial and sign a written informed consent form;
  • Age ≤18 years, gender not limited;
  • Karnofsky (≥16 years old) or Lansky (<16 years old) physical status score (Appendix II) of at least 50;
  • Patients diagnosed with high-risk, recurrent/refractory neuroblastoma in children according to clinical diagnostic criteria, who have undergone comprehensive treatment (surgery, chemotherapy, radiotherapy ± stem cell transplantation ± GD2 monoclonal antibody therapy);
  • Expected survival period of at least 12 weeks;
  • The patient must have fully recovered from the acute toxic effects of all previous anticancer chemotherapy, such as recovery to grade I after bone marrow suppression;
  • Bone marrow suppressive chemotherapy: At least 21 days after the last bone marrow suppressive chemotherapy (if nitrosoureas were used previously, then 42 days);
  • Investigational drugs or anticancer therapies other than chemotherapy: Must not be used within 28 days before the planned start of NK cell immunotherapy. Full recovery from the clinically significant toxicity of that therapy must be confirmed;
  • Hematopoietic growth factors: At least 14 days after the last dose of long-acting growth factors or 3 days after the last dose of short-acting growth factors;
  • X-ray therapy (XRT): At least 14 days after local palliative XRT (small field port); if other substantial bone marrow (BM) irradiation is involved, including prior radioactive iodine metaiodobenzylguanidine (131I-MIBG) treatment, it must end at least 42 days ago;
  • Stem cell infusion without total body irradiation (TBI): No active graft-versus-host disease, must have ended at least 56 days after transplantation or stem cell infusion;
  • Laboratory tests during the screening period must meet the following conditions:
  • Absolute neutrophil count (ANC) ≥1.0×10\^9/L (if bone marrow involvement, then ANC ≥0.5×10\^9/L)
  • Platelet count (PLT) ≥75×10\^9/L (if bone marrow involvement, then PLT ≥20×10\^9/L)
  • Bilirubin ≤1.5 times the upper limit of normal (ULN)
  • Creatinine ≤1.5 times ULN (calculated using the standard Cockcroft-Gault formula)
  • ALT/AST ≤3 times ULN (if there is liver metastasis, this can be relaxed to 5 times ULN)
  • During the study period, able to comply with outpatient treatment, laboratory monitoring, and necessary clinical visits; parents/guardians of pediatric or adolescent participants are capable of understanding, consenting to, and signing the informed consent form (ICF) and applicable child assent forms before initiating any protocol-related procedures; with parental/guardian consent, the participant is capable of expressing their consent (when applicable).

Exclusion Criteria:

Patients who meet any of the following criteria are not eligible for this trial:

  • Symptomatic brain metastases (patients whose brain metastases have been treated and whose symptoms have been stable for more than two months prior to enrollment may be enrolled, but must be confirmed by cranial MRI, CT, or venography as having no symptoms of cerebral hemorrhage);
  • Suffering from the following cardiovascular diseases: grade II or higher myocardial ischemia or myocardial infarction, poorly controlled arrhythmias (including QTc interval ≥450 ms for males and ≥470 ms for females); according to the NYHA standard (Appendix Three), class III-IV heart failure, or echocardiography indicating left ventricular ejection fraction (LVEF) <50%;
  • Having a history of interstitial lung disease or suffering from interstitial lung disease at the same time;
  • Coagulation disorders (INR >1.5 or prothrombin time (PT) >ULN +4 seconds or APTT >1.5 ULN), with a tendency to bleed or currently receiving thrombolytic or anticoagulant therapy;
  • Arterial/venous thromboembolic events occurring within 12 months before enrollment, such as cerebrovascular accidents (including transient ischemic attacks, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism;
  • Known hereditary or acquired bleeding and thrombosis tendencies (such as hemophilia patients, coagulation disorders, thrombocytopenia, splenomegaly, etc.);
  • Long-term unhealed wounds or fractures (except pathological fractures caused by tumors);
  • Receiving major surgery or experiencing severe traumatic injuries, fractures, or ulcers within 4 weeks before enrollment;
  • Factors significantly affecting the absorption of oral medications, such as inability to swallow, chronic diarrhea, and intestinal obstruction;
  • Experiencing abdominal fistula, gastrointestinal perforation, or abdominal abscess within 6 months before enrollment;
  • Routine urine tests showing proteinuria ≥ +, and confirmed 24-hour urine protein quantification ≥1.0 g;
  • Symptomatic serosal effusions requiring symptomatic treatment (including pleural effusion, ascites, pericardial effusion); Note: Asymptomatic serosal effusions can be enrolled, symptomatic serosal effusions after active symptomatic treatment (anticancer drugs cannot be used for treating serosal effusions), judged by the investigator to meet the enrollment criteria can be enrolled;
  • Active infections requiring antimicrobial treatment (e.g., needing antibacterial drugs, antiviral drugs, excluding chronic hepatitis B antiviral treatment, antifungal drug treatment);
  • History of psychoactive substance abuse that cannot be quit or has mental disorders;
  • Participated in other antitumor drug clinical trials within 4 weeks before enrollment;
  • Receiving systemic hormone therapy or undergoing any form of immunosuppressive therapy within 2 weeks before the first administration;
  • In the past 2 years, suffered from active autoimmune diseases requiring systemic treatment (such as using disease-modifying drugs, corticosteroids, or immunosuppressants); Note: Substitutive treatments (such as thyroxine, insulin, or physiological corticosteroid replacement therapy for adrenal or pituitary insufficiency) do not count as systemic treatment;
  • Contraindications for IL-2 use;
  • Suffering from active infections requiring intravenous systemic treatment;
  • Vaccinated with live vaccines within one month before the first use of the study drug, seasonal influenza vaccination with inactivated virus vaccines is allowed, but intranasal attenuated live influenza vaccines are not allowed;
  • Previous or concomitant other uncured malignancies, cured skin basal cell carcinoma, cervical carcinoma in situ, and superficial bladder cancer are excluded;
  • Other conditions judged by the investigator that may affect the conduct of the clinical study and the determination of study results;
  • Virological tests during the screening period show any of the following:
  • HBsAg positive and HBV DNA exceeds the upper limit of normal
  • Anti-HCV positive and HCV RNA positive
  • HIV positive
  • Undergone allogeneic tissue/organ transplantation;
  • Poor compliance, unable to cooperate with the clinical study.

Quoted from ClinicalTrials.gov, NCT06631391, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06631391, read on 13 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06631391